PolyPid Initiates D-PLEX₁₀₀ NDA Submission to FDA for Surgical Site Infection Prevention
PYPD sits 81% above its 52-week low of $2.3.
Summary
PolyPid Ltd. has begun its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀, a key step towards commercialization for preventing surgical site infections, with completion expected in Q2 2026.
Key Events · Product Development and Regulatory · PYPD
-
NDA Submission Initiated
PolyPid has started the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients.
-
Rolling Review Under Fast Track
The NDA is being submitted under the FDA's Fast Track designation, allowing for a rolling review process. The Chemistry, Manufacturing and Controls (CMC) and nonclinical sections have been submitted, with the clinical section expected in Q2 2026.
-
Follows Positive Phase 3 Results
This submission follows positive results from the Phase 3 SHIELD II trial, where D-PLEX₁₀₀ achieved a statistically significant 60% relative risk reduction in SSI incidence.
-
Commercialization Partnership Discussions
The company is actively advancing discussions for a U.S. commercialization partnership for D-PLEX₁₀₀.
Analysis · PYPD · Industrial Applications And Services
PolyPid Ltd. has commenced the New Drug Application (NDA) submission for its lead product candidate, D-PLEX₁₀₀, to the FDA. This is a critical regulatory milestone for the company, moving its primary asset closer to potential commercialization. The Fast Track designation allows for a rolling review, which could expedite the approval process. Given the positive Phase 3 SHIELD II trial results and Breakthrough Therapy Designation, this submission significantly de-risks the product's path to market. For a company of PolyPid's size, successful NDA submission and potential approval are transformative events, further bolstered by ongoing discussions for a U.S. commercialization partnership.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYPD was trading at $4.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $80.3M. The 52-week trading range was $2.30 to $5.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.